191 related articles for article (PubMed ID: 22583928)
1. Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy.
James LK; Bowen H; Calvert RA; Dodev TS; Shamji MH; Beavil AJ; McDonnell JM; Durham SR; Gould HJ
J Allergy Clin Immunol; 2012 Sep; 130(3):663-670.e3. PubMed ID: 22583928
[TBL] [Abstract][Full Text] [Related]
2. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.
Zieglmayer P; Focke-Tejkl M; Schmutz R; Lemell P; Zieglmayer R; Weber M; Kiss R; Blatt K; Valent P; Stolz F; Huber H; Neubauer A; Knoll A; Horak F; Henning R; Valenta R
EBioMedicine; 2016 Sep; 11():43-57. PubMed ID: 27650868
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
[TBL] [Abstract][Full Text] [Related]
5. Nasal allergen-neutralizing IgG
Shamji MH; Kappen J; Abubakar-Waziri H; Zhang J; Steveling E; Watchman S; Kouser L; Eifan A; Switzer A; Varricchi G; Marone G; Couto-Francisco NC; Calderon M; Durham SR
J Allergy Clin Immunol; 2019 Mar; 143(3):1067-1076. PubMed ID: 30445057
[TBL] [Abstract][Full Text] [Related]
6. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy.
Ball T; Sperr WR; Valent P; Lidholm J; Spitzauer S; Ebner C; Kraft D; Valenta R
Eur J Immunol; 1999 Jun; 29(6):2026-36. PubMed ID: 10382766
[TBL] [Abstract][Full Text] [Related]
7. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies.
James LK; Shamji MH; Walker SM; Wilson DR; Wachholz PA; Francis JN; Jacobson MR; Kimber I; Till SJ; Durham SR
J Allergy Clin Immunol; 2011 Feb; 127(2):509-516.e1-5. PubMed ID: 21281875
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy.
Wachholz PA; Soni NK; Till SJ; Durham SR
J Allergy Clin Immunol; 2003 Nov; 112(5):915-22. PubMed ID: 14610480
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.
Focke-Tejkl M; Weber M; Niespodziana K; Neubauer A; Huber H; Henning R; Stegfellner G; Maderegger B; Hauer M; Stolz F; Niederberger V; Marth K; Eckl-Dorna J; Weiss R; Thalhamer J; Blatt K; Valent P; Valenta R
J Allergy Clin Immunol; 2015 May; 135(5):1207-7.e1-11. PubMed ID: 25441634
[TBL] [Abstract][Full Text] [Related]
10. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.
Nouri-Aria KT; Wachholz PA; Francis JN; Jacobson MR; Walker SM; Wilcock LK; Staple SQ; Aalberse RC; Till SJ; Durham SR
J Immunol; 2004 Mar; 172(5):3252-9. PubMed ID: 14978133
[TBL] [Abstract][Full Text] [Related]
11. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells.
Scadding GW; Shamji MH; Jacobson MR; Lee DI; Wilson D; Lima MT; Pitkin L; Pilette C; Nouri-Aria K; Durham SR
Clin Exp Allergy; 2010 Apr; 40(4):598-606. PubMed ID: 20184605
[TBL] [Abstract][Full Text] [Related]
12. Determination of allergen specificity by heavy chains in grass pollen allergen-specific IgE antibodies.
Gadermaier E; Flicker S; Lupinek C; Steinberger P; Valenta R
J Allergy Clin Immunol; 2013 Apr; 131(4):1185-93, 1193.e1-6. PubMed ID: 23206656
[TBL] [Abstract][Full Text] [Related]
13. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy.
Aasbjerg K; Backer V; Lund G; Holm J; Nielsen NC; Holse M; Wagtmann VR; Würtzen PA
Clin Exp Allergy; 2014 Mar; 44(3):417-28. PubMed ID: 24734285
[TBL] [Abstract][Full Text] [Related]
14. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination.
Ball T; Linhart B; Sonneck K; Blatt K; Herrmann H; Valent P; Stoecklinger A; Lupinek C; Thalhamer J; Fedorov AA; Almo SC; Valenta R
Allergy; 2009 Apr; 64(4):569-80. PubMed ID: 19243361
[TBL] [Abstract][Full Text] [Related]
15. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
16. Possible therapeutic potential of a recombinant group 2 grass pollen allergen-specific antibody fragment.
Gadermaier E; Flicker S; Blatt K; Valent P; Valenta R
Allergy; 2014 Feb; 69(2):261-4. PubMed ID: 24251384
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.
Niederberger V; Neubauer A; Gevaert P; Zidarn M; Worm M; Aberer W; Malling HJ; Pfaar O; Klimek L; Pfützner W; Ring J; Darsow U; Novak N; Gerth van Wijk R; Eckl-Dorna J; Focke-Tejkl M; Weber M; Müller HH; Klinger J; Stolz F; Breit N; Henning R; Valenta R
J Allergy Clin Immunol; 2018 Aug; 142(2):497-509.e9. PubMed ID: 29361332
[TBL] [Abstract][Full Text] [Related]
18. Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG
Eckl-Dorna J; Weber M; Stanek V; Linhart B; Ristl R; Waltl EE; Villazala-Merino S; Hummel A; Focke-Tejkl M; Froeschel R; Neubauer A; Henning R; Perkmann T; Valenta R; Niederberger V
EBioMedicine; 2019 Dec; 50():421-432. PubMed ID: 31786130
[TBL] [Abstract][Full Text] [Related]
19. Oligoclonal analysis of the atopic T cell response to the group 1 allergen of Cynodon dactylon (bermuda grass) pollen: pre- and post-allergen-specific immunotherapy.
Eusebius NP; Papalia L; Suphioglu C; McLellan SC; Varney M; Rolland JM; O'Hehir RE
Int Arch Allergy Immunol; 2002 Mar; 127(3):234-44. PubMed ID: 11979049
[TBL] [Abstract][Full Text] [Related]
20. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.
Shamji MH; Ljørring C; Francis JN; Calderon MA; Larché M; Kimber I; Frew AJ; Ipsen H; Lund K; Würtzen PA; Durham SR
Allergy; 2012 Feb; 67(2):217-26. PubMed ID: 22077562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
